Join our mailing list!
(Your shopping cart is empty)
Diane Publishing Books
Rare Diseases: Too Early to Gauge Effeectiveness of FDAäó»s Pediatric Voucher Program
Marcia Crosse (au)
Almost 7,999 rare diseases, most of which are serious or life-threatening, affect more than 25 million Americans. About half of all rare diseases affect children, and few of these diseases have viable treatments. To encourage the development of drugs to treat or prevent rare pediatric diseases, the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 authorized FDA to award a priority review voucher to a drug sponsor upon approval of that sponsoräó»s drug to treat a rare pediatric disease. A drug sponsor can later redeem the voucher when submitting another new drug application to treat any disease or condition in adults or children, or sell or transfer the voucher to another sponsor. A voucher entitles a sponsor to a 6-month priority review by FDA rather than the 10-month standard review. This report examined what is known abut the effectiveness of the pediatric voucher program. Table and figure. This is a print on demand report.
Essential Tibetan Buddhism
Commonwealth of Science: ANZAAS & the Scientific Enterprise in Australia, 1888-1988
Wordsworth Dictionary of the American West
Women of Strength: Biographies of 106 Who Have Excelled in Traditionally Male Fields, A.D. 61 to the Present
Share your knowledge of this product with other customers...
Be the first to write a review
Diane Publishing Co
PO Box 617
Darby, PA 19023-0617
Become an Affiliate
Send Us Feedback
Copyright ï¿½ 2004 Diane Publishing Company. All Rights Reserved.